Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2020 | Arterial Occlusive Disease | Research article

Comparison of efficacy and safety of drug-eluting versus uncoated balloon angioplasty for femoropopliteal arterial occlusive disease: a meta-analysis

Authors: Hai Feng, Xueming Chen, Xiaobo Guo, Zhe Zhang, Zhiwen Zhang, Bin Liu, Lishan Lian

Published in: BMC Cardiovascular Disorders | Issue 1/2020

Abstract

Background

This quantitative meta-analysis was conducted to evaluate the efficacy and safety of drug-eluting balloon (DEB) vs. uncoated balloon (UCB) in patients with femoropopliteal arterial occlusive disease.

Methods

Electronic databases were searched to identify randomized controlled trials (RCTs) that compared DEB and UCB till November 2018. The random-effects model was used for conducting pooled analyses.

Results

Seventeen RCTs with 2706 patients were included in the final meta-analysis. Patients who received DEB had higher levels of minimal luminal diameter (MLD) at 6 (WMD: 0.77; 95%CI: 0.53 to 1.02; P < 0.001) and 12 months (WMD: 1.33; 95%CI: 0.93 to 1.73; P < 0.001) than those who received UCB. DEB reduced the late lumen loss (LLL) levels after 6 (WMD: -0.57; 95%CI: − 1.07 to − 0.06; P = 0.029) and 12 months (WMD: -0.95; 95%CI: − 1.28 to − 0.62; P < 0.001). DEB was found not superior over UCB on primary patency after 6 months (RR: 1.44; 95%CI: 0.88–2.35; P = 0.149), whereas DEB increased the primary patency after 12 (RR: 1.51; 95%CI: 1.25–1.83; P < 0.001) and 24 months (RR: 1.51; 95%CI: 1.30–1.77; P < 0.001). Patients who received DEB had reduced the risk of restenosis after 6 (RR: 0.47; 95%CI: 0.33–0.67; P < 0.001) and 12 months (RR: 0.55; 95%CI: 0.35–0.85; P = 0.008). DEB reduced the risk of major adverse events after 6 (RR: 0.30; 95%CI: 0.14–0.61; P = 0.001), 12 (RR: 0.49; 95%CI: 0.32–0.76; P = 0.001) and 24 months (RR: 0.62; 95%CI: 0.41–0.92; P = 0.018).

Conclusions

DEB yielded additional benefits on MLD, LLL, primary patency, restenosis, TLR, and major adverse events than UCB in patients with femoropopliteal arterial occlusive disease.

Available only for authorised users

Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053–61. https://doi.org/10.1161/circulationaha.109.865600.CrossRefPubMed

Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–40. https://doi.org/10.1016/s0140-6736(13)61249-0.CrossRefPubMed

McDermott MM, Kibbe M, Guralnik JM, Pearce WH, Tian L, Liao Y, et al. Comparative effectiveness study of self-directed walking exercise, lower extremity revascularization, and functional decline in peripheral artery disease. J Vasc Surg. 2013;57:990–6.e1. https://doi.org/10.1016/j.jvs.2012.09.068.CrossRefPubMedPubMedCentral

Schillinger M, Minar E. Claudication: treatment options for femoropopliteal disease. Prog Cardiovasc Dis. 2011;54:41–6. https://doi.org/10.1016/j.pcad.2011.04.003.CrossRefPubMed

Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J. 2005;26:1262–8. https://doi.org/10.1093/eurheartj/ehi098.CrossRefPubMed

Jongsma H, Bekken JA, de Vries JP, Verhagen HJ, Fioole B. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty in patients with femoropopliteal arterial occlusive disease. J Vasc Surg. 2016;64:1503–14. https://doi.org/10.1016/j.jvs.2016.05.084.CrossRefPubMed

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097.CrossRefPubMedPubMedCentral

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.CrossRefPubMed

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed

10.

Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Mak. 2005;25:646–54. https://doi.org/10.1177/0272989x05282643.CrossRef

11.

Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analyses. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions 501. edn. Oxford: The Cochrane Collaboration; 2008.

12.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. https://doi.org/10.1136/bmj.327.7414.557.CrossRefPubMedPubMedCentral

13.

Tobias A. Assessing the influence of a single study in meta-analysis. Stata Tech Bull. 1999;47:15–7.

14.

Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559–73. https://doi.org/10.1002/sim.1187.CrossRefPubMed

15.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentral

16.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed

17.

Jia X, Zhang J, Zhuang B, Fu W, Wu D, Wang F, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Interv. 2016;9:1941–9. https://doi.org/10.1016/j.jcin.2016.06.055.CrossRefPubMed

18.

Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22:14–21. https://doi.org/10.1177/1526602814564383.CrossRefPubMed

19.

Zeller T, Beschorner U, Pilger E, Bosiers M, Deloose K, Peeters P, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK’S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015;8:1614–22. https://doi.org/10.1016/j.jcin.2015.07.011.CrossRefPubMed

20.

Albrecht T, Waliszewski M, Roca C, Redlich U, Tautenhahn J, Pech M, et al. Two-year clinical outcomes of the CONSEQUENT trial: can Femoropopliteal lesions be treated with sustainable clinical results that are economically sound? Cardiovasc Intervent Radiol. 2018;41:1008–14. https://doi.org/10.1007/s00270-018-1940-1.CrossRefPubMed

21.

Liistro F, Grotti S, Porto I, Angioli P, Ricci L, Ducci K, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6:1295–302. https://doi.org/10.1016/j.jcin.2013.07.010.CrossRefPubMed

22.

Fanelli F, Cannavale A, Boatta E, Corona M, Lucatelli P, Wlderk A, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther. 2012;19:571–80. https://doi.org/10.1583/jevt-12-3926mr.1.CrossRefPubMed

23.

Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136:1102–13. https://doi.org/10.1161/circulationaha.117.028893.CrossRefPubMedPubMedCentral

24.

Schroeder H, Werner M, Meyer DR, Reimer P, Kruger K, Jaff MR, et al. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon). Circulation. 2017;135:2227–36. https://doi.org/10.1161/circulationaha.116.026493.CrossRefPubMedPubMedCentral

25.

Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502. https://doi.org/10.1161/circulationaha.114.011004.CrossRefPubMedPubMedCentral

26.

Debing E, Aerden D, Vanhulle A, Gallala S, von Kemp K. Paclitaxel-coated versus plain old balloon angioplasty for the treatment of infrainguinal arterial disease in diabetic patients: the Belgian diabetic IN.PACT Trial. J Cardiovasc Surg (Torino). 2017;58:528–34. https://doi.org/10.23736/s0021-9509.16.09685-3.CrossRef

27.

Ott I, Cassese S, Groha P, Steppich B, Hadamitzky M, Ibrahim T, et al. Randomized comparison of paclitaxel-eluting balloon and stenting versus plain balloon plus stenting versus directional atherectomy for femoral artery disease (ISAR-STATH). Circulation. 2017;135:2218–26. https://doi.org/10.1161/circulationaha.116.025329.CrossRefPubMed

28.

Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–9. https://doi.org/10.1016/j.jcin.2013.05.022.CrossRefPubMed

29.

Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–53. https://doi.org/10.1056/NEJMoa1406235.CrossRefPubMed

30.

Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–40. https://doi.org/10.1161/circinterventions.112.971630.CrossRefPubMed

31.

Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. JACC Cardiovasc Interv. 2016;9:1386–92. https://doi.org/10.1016/j.jcin.2016.04.012.CrossRefPubMed

32.

Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–99. https://doi.org/10.1056/NEJMoa0706356.CrossRefPubMed

33.

Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–65. https://doi.org/10.1161/circulationaha.107.735985.CrossRefPubMed

34.

Cassese S, Byrne RA, Ott I, Ndrepepa G, Nerad M, Kastrati A, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2012;5:582–9. https://doi.org/10.1161/circinterventions.112.969972.CrossRefPubMed

35.

Kayssi A, Al-Atassi T, Oreopoulos G, Roche-Nagle G, Tan KT, Rajan DK. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. 2016:Cd011319. https://doi.org/10.1002/14651858.CD011319.pub2.

36.

Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, et al. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv. 2016;9:1731–42. https://doi.org/10.1016/j.jcin.2016.06.008.CrossRefPubMed

37.

Jaff MR, Nelson T, Ferko N, Martinson M, Anderson LH, Hollmann S. Endovascular Interventions for femoropopliteal peripheral artery disease: a network meta-analysis of current technologies. J Vasc Interv Radiol. 2017;28:1617–27.e1. https://doi.org/10.1016/j.jvir.2017.08.003.CrossRefPubMed

38.

Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245. https://doi.org/10.1161/JAHA.118.011245.CrossRefPubMedPubMedCentral

39.

Klumb C, Lehmann T, Aschenbach R, Eckardt N, Teichgräber U. Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2019;16:42–50. https://doi.org/10.1016/j.eclinm.2019.09.004.CrossRefPubMedPubMedCentral

40.

Cornejo Del Rio V, Mostaza J, Lahoz C, Sanchez-Arroyo V, Sabin C, Lopez S, et al. Prevalence of peripheral artery disease (PAD) and factors associated: an epidemiological analysis from the population-based screening PRE-diabetes and type 2 DIAbetes (SPREDIA-2) study. PLoS One. 2017;12:e0186220. https://doi.org/10.1371/journal.pone.0186220.CrossRefPubMedPubMedCentral

41.

Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2017;14:156–70. https://doi.org/10.1038/nrcardio.2016.179.CrossRefPubMed

42.

Steven S, Daiber A, Dopheide JF, Munzel T, Espinola-Klein C. Peripheral artery disease, redox signaling, oxidative stress - basic and clinical aspects. Redox Biol. 2017;12:787–97. https://doi.org/10.1016/j.redox.2017.04.017.CrossRefPubMedPubMedCentral

43.

Rocha-Singh KJ, Duval S, Jaff MR, et al. Mortality and paclitaxel-coated devices: an individual patient data meta-analysis. Circulation. 2020;141(23):1859–69. https://doi.org/10.1161/CIRCULATIONAHA.119.044697.CrossRefPubMedPubMedCentral

44.

Freisinger E, Koeppe J, Gerss J, et al. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J. 2019:ehz698. https://doi.org/10.1093/eurheartj/ehz698 [published online ahead of print, 2019 Oct 8].

Title: Comparison of efficacy and safety of drug-eluting versus uncoated balloon angioplasty for femoropopliteal arterial occlusive disease: a meta-analysis
Authors: Hai Feng
Xueming Chen
Xiaobo Guo
Zhe Zhang
Zhiwen Zhang
Bin Liu
Lishan Lian
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Arterial Occlusive Disease
Diabetes
Published in: BMC Cardiovascular Disorders / Issue 1/2020
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-020-01667-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparison of efficacy and safety of drug-eluting versus uncoated balloon angioplasty for femoropopliteal arterial occlusive disease: a meta-analysis

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Susceptible gene polymorphism in patients with three-vessel coronary artery disease

Preoperative exercise and recovery after cardiac surgery: a meta-analysis

Physical activity and the risk of sudden cardiac death: a systematic review and meta-analysis of prospective studies

Genetic forms and pathophysiology of essential arterial hypertension in minor indigenous peoples of Russia

Identification of transcription factors MYC and C/EBPβ mediated regulatory networks in heart failure based on gene expression omnibus datasets

Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page